Kunitomi, Yuji
Nakashima, Masayuki
Takeuchi, Masato
Kawakami, Koji http://orcid.org/0000-0002-7477-4071
Article History
Received: 3 October 2022
Accepted: 17 January 2023
First Online: 26 January 2023
Declarations
:
: This study was approved by the Ethics Committee of the Graduate School and Faculty of Medicine, Kyoto University (approval number: R3038; date: July 1, 2021). This study was performed in accordance with the ethical guidelines for medical and health research involving human subjects by the Ministry of Health, Labor, and Welfare.
: The need for informed consent was waived because anonymized data were used.
: Not applicable.
: Y. K. is a company employee of Taiho Pharmaceutical Co., Ltd. M. T. received a consultation fee from Eisai Co., Ltd. K. K. received consultation fees from LEBER, Inc., JMDC Inc., Shin Nippon Biomedical Laboratories, Ltd., and Advanced Medical Care Inc.; executive compensation from Cancer Intelligence Care Systems, Inc.; honoraria from Mitsubishi Chemical Holdings Corporation, Mitsubishi Corporation, Pharma Business Academy, and Toppan Inc.; research funds from Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., Mitsubishi Corporation., and Real World Data, Co., Ltd.; and held stock in Real World Data, Co., Ltd. The other authors have no direct or indirect conflicts of interest.